Prediction of adult asthma risk in early childhood using novel adult asthma predictive risk scores.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
11 2023
Historique:
revised: 30 07 2023
received: 29 01 2023
accepted: 02 08 2023
pmc-release: 01 11 2024
medline: 13 11 2023
pubmed: 4 9 2023
entrez: 3 9 2023
Statut: ppublish

Résumé

Numerous risk scores have been developed to predict childhood asthma. However, they may not predict asthma beyond childhood. We aim to create childhood risk scores that predict development and persistence of asthma up to young adult life. The Isle of Wight Birth Cohort (n = 1456) was prospectively assessed up to 26 years of age. Asthma predictive scores were developed based on factors during the first 4 years, using logistic regression and tested for sensitivity, specificity and area under the curve (AUC) for prediction of asthma at (i) 18 and (ii) 26 years, and persistent asthma (PA) (iii) at 10 and 18 years, and (iv) at 10, 18 and 26 years. Models were internally and externally validated. Four models were generated for prediction of each asthma outcome. ASthma PredIctive Risk scorE (ASPIRE)-1: a 2-factor model (recurrent wheeze [RW] and positive skin prick test [+SPT] at 4 years) for asthma at 18 years (sensitivity: 0.49, specificity: 0.80, AUC: 0.65). ASPIRE-2: a 3-factor model (RW, +SPT and maternal rhinitis) for asthma at 26 years (sensitivity: 0.60, specificity: 0.79, AUC: 0.73). ASPIRE-3: a 3-factor model (RW, +SPT and eczema at 4 years) for PA-18 (sensitivity: 0.63, specificity: 0.87, AUC: 0.77). ASPIRE-4: a 3-factor model (RW, +SPT at 4 years and recurrent chest infection at 2 years) for PA-26 (sensitivity: 0.68, specificity: 0.87, AUC: 0.80). ASPIRE-1 and ASPIRE-3 scores were replicated externally. Further assessments indicated that ASPIRE-1 can be used in place of ASPIRE-2-4 with same predictive accuracy. ASPIRE predicts persistent asthma up to young adult life.

Sections du résumé

BACKGROUND
Numerous risk scores have been developed to predict childhood asthma. However, they may not predict asthma beyond childhood. We aim to create childhood risk scores that predict development and persistence of asthma up to young adult life.
METHODS
The Isle of Wight Birth Cohort (n = 1456) was prospectively assessed up to 26 years of age. Asthma predictive scores were developed based on factors during the first 4 years, using logistic regression and tested for sensitivity, specificity and area under the curve (AUC) for prediction of asthma at (i) 18 and (ii) 26 years, and persistent asthma (PA) (iii) at 10 and 18 years, and (iv) at 10, 18 and 26 years. Models were internally and externally validated.
RESULTS
Four models were generated for prediction of each asthma outcome. ASthma PredIctive Risk scorE (ASPIRE)-1: a 2-factor model (recurrent wheeze [RW] and positive skin prick test [+SPT] at 4 years) for asthma at 18 years (sensitivity: 0.49, specificity: 0.80, AUC: 0.65). ASPIRE-2: a 3-factor model (RW, +SPT and maternal rhinitis) for asthma at 26 years (sensitivity: 0.60, specificity: 0.79, AUC: 0.73). ASPIRE-3: a 3-factor model (RW, +SPT and eczema at 4 years) for PA-18 (sensitivity: 0.63, specificity: 0.87, AUC: 0.77). ASPIRE-4: a 3-factor model (RW, +SPT at 4 years and recurrent chest infection at 2 years) for PA-26 (sensitivity: 0.68, specificity: 0.87, AUC: 0.80). ASPIRE-1 and ASPIRE-3 scores were replicated externally. Further assessments indicated that ASPIRE-1 can be used in place of ASPIRE-2-4 with same predictive accuracy.
CONCLUSION
ASPIRE predicts persistent asthma up to young adult life.

Identifiants

pubmed: 37661293
doi: 10.1111/all.15876
pmc: PMC10840748
mid: NIHMS1927719
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2969-2979

Subventions

Organisme : Medical Research Council
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI121426
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI121226
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL082925
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

Am J Respir Crit Care Med. 2004 Jul 1;170(1):78-85
pubmed: 15028559
Eur Respir J. 2003 Nov;22(5):767-71
pubmed: 14621083
Am J Respir Crit Care Med. 2014 Jun 1;189(11):1351-8
pubmed: 24796409
Lancet Respir Med. 2018 Jul;6(7):535-544
pubmed: 29628376
Respir Res. 2014 Nov 29;15:153
pubmed: 25472820
Prim Care Respir J. 2014 Mar;23(1):52-9
pubmed: 24496487
Chest. 2005 Feb;127(2):502-8
pubmed: 15705988
Lancet. 2008 Sep 20;372(9643):1100-6
pubmed: 18805338
Respir Med. 2012 Mar;106(3):329-37
pubmed: 22212639
J Allergy Clin Immunol. 2009 Nov;124(5):903-10.e1-7
pubmed: 19665765
Lancet. 2008 Sep 20;372(9643):1058-64
pubmed: 18805334
J Allergy Clin Immunol. 2019 May;143(5):1803-1810.e2
pubmed: 30554722
J Allergy Clin Immunol. 2017 Oct;140(4):895-906
pubmed: 28987219
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1646-1655
pubmed: 32649838
J Allergy Clin Immunol. 2014 Jun;133(6):1572-8.e3
pubmed: 24495434
Clin Exp Allergy. 2005 Jul;35(7):933-40
pubmed: 16008681
Curr Opin Allergy Clin Immunol. 2022 Apr 1;22(2):115-122
pubmed: 35197433
J Allergy Clin Immunol. 2012 Aug;130(2):287-96; quiz 297-8
pubmed: 22664162
Pediatrics. 2001 Aug;108(2):E33
pubmed: 11483843
Lancet Respir Med. 2015 Dec;3(12):973-84
pubmed: 26597131
Int J Epidemiol. 2018 Aug 1;47(4):1043-1044i
pubmed: 29547889
J Asthma. 2011 Dec;48(10):1015-21
pubmed: 22022892
J Allergy Clin Immunol. 2010 Sep;126(3):498-504.e1-6
pubmed: 20816186
J Allergy Clin Immunol. 2010 Aug;126(2):212-6
pubmed: 20624655
Int J Clin Pract. 2007 Aug;61(8):1371-4
pubmed: 17627712
Eur Respir J. 2007 Jul;30(1):62-5
pubmed: 17360725
J Clin Epidemiol. 2006 Nov;59(11):1207-12
pubmed: 17027432
Allergy. 2023 Nov;78(11):2969-2979
pubmed: 37661293
J Allergy Clin Immunol. 2014 Jan;133(1):111-8.e1-13
pubmed: 23891353
N Engl J Med. 2003 Oct 9;349(15):1414-22
pubmed: 14534334
Eur Respir J. 2004 Jan;23(1):66-70
pubmed: 14738233
Thorax. 2008 Jan;63(1):8-13
pubmed: 17615086
Pediatr Allergy Immunol. 2020 Aug;31(6):616-627
pubmed: 32181536

Auteurs

Abdal J Farhan (AJ)

The David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Dilini M Kothalawala (DM)

NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.

Ramesh J Kurukulaaratchy (RJ)

The David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.

Raquel Granell (R)

MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Angela Simpson (A)

Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK.

Clare Murray (C)

Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester Academic Health Science Centre, and Manchester University NHS Foundation Trust, Manchester, UK.

Adnan Custovic (A)

National Heart and Lung Institute, Imperial College London, London, UK.

Graham Roberts (G)

The David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.

Hongmei Zhang (H)

Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee, USA.

S Hasan Arshad (SH)

The David Hide Asthma and Allergy Research Centre, St. Mary's Hospital, Isle of Wight, UK.
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH